Lees-Rolfe Garth
Inhibikase Therapeutics, Inc. · Chief Financial Officer
Lees-Rolfe Garth is listed in public filings as officer: Chief Financial Officer. This Lees-Rolfe Garth insider trading page organizes Form 4 disclosures, reported purchases and sales, transaction dates, share amounts, related issuers, and historical insider activity so readers can review the person's public trading record in one place. Companies and tickers connected to this insider trading profile include Inhibikase Therapeutics, Inc. (IKT). Investors use Lees-Rolfe Garth's insider trading disclosures to study buying and selling patterns, position changes, company-specific activity, and the source evidence behind each reported transaction.
Latest Actions
| Company | Holding Value | Last Transaction | Amount | Transaction Price | Current Price |
|---|---|---|---|---|---|
| $090k shares | OtherJan 21, 2025 | $194.4K90k shares | $2.16 | -- | |
| $113k90k shares | Grant / ExerciseJan 21, 2025 | $113.4K90k shares | $1.26 | -- | |
| $05.8k shares | OtherJan 21, 2025 | $22.1K5.8k shares | $3.79 | -- | |
| $7.4k5.8k shares | Grant / ExerciseJan 21, 2025 | $7.4K5.8k shares | $1.26 | -- |
Insider Trades History
| Company | Holding Value | Last Transaction | Amount | Transaction Price | Current Price |
|---|---|---|---|---|---|
| $684k432.9k shares | Grant / ExerciseJan 3, 2025 | $683.9K432.9k shares | $1.58 | -- | |
| $593k470.9k shares | Grant / ExerciseJan 3, 2025 | $593.3K470.9k shares | $1.26 | -- | |
| $341k235.4k shares | Grant / ExerciseJan 3, 2025 | $341.3K235.4k shares | $1.45 | -- |